About Premedium Pharmaceuticals
Premedium Pharmaceuticals is a company based in Gurugram (India). It operates as a B2B. The company has 12 employees. Premedium Pharmaceuticals offers products and services including Artepitant 150 IV Injection, Preciplatin 10 Mg, Preciplatin 50 Mg, Artetum Injection 1.5g, and Artezone Injection 1g. Premedium Pharmaceuticals operates in a competitive market with competitors including Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
- Headquarter Gurugram, India
- Employees 12
- SectorsHealthcare
- Email••••••••
- Website premediumpharmaceuticals.com
- Social Facebook
- Legal Name Premedium Pharmaceuticals Private Limited
- Date of Incorporation 09 Oct, 2018
- Jurisdiction Delhi, India
- Annual Revenue₹9.67 Cr
FY 2025 · +29% YoY
- Net Profit₹1.49 Cr
FY 2025 · 15% margin
- EBITDA₹1.55 Cr
FY 2025 · 16% margin
- Employee Count12
Associated legal entities of Premedium Pharmaceuticals
Premedium Pharmaceuticals operates through Premedium Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Premedium Pharmaceuticals Private Limited CIN U24200DL2018PTC340319 | Active | 09 Oct 2018 | Delhi, Delhi | ₹9.7 Cr | 12 | 5 | View details |
Products & Services of Premedium Pharmaceuticals
Premedium Pharmaceuticals offers a comprehensive portfolio of products and services, including Artepitant 150 IV Injection, Preciplatin 10 Mg, Preciplatin 50 Mg, Artetum Injection 1.5g, and Artezone Injection 1g.
IV treatment for chemotherapy-induced nausea and vomiting
Medication for cancer therapy and tumor treatment
Dosage for oncology and related medical uses
Therapeutic injection for specific medical conditions
Injection for healthcare and treatment purposes
Advanced dosage for medical therapies
Injection for pain or condition management
Mono therapy for targeted health issues
Dosage for specialized pharmaceutical needs
Drug for various therapeutic applications
High-dosage treatment option for patients
Board of directors of Premedium Pharmaceuticals Private Limited (Premedium Pharmaceuticals)
Premedium Pharmaceuticals Private Limited is the primary company behind Premedium Pharmaceuticals. The board of Premedium Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Sanjiv Kumar Kothari, appointed in 2018. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjiv Kumar Kothari DIN 00760651 | Director | 09 Oct 2018 | 8 yrs | Premedium Pharmaceuticals Private Limited |
| Saras Malik DIN 08536003 | Director | 14 Aug 2019 | 7 yrs 2 mo | Premedium Pharmaceuticals Private Limited |
| Dilip Birdi DIN 08134919 | Whole-time director | 30 Dec 2019 | 6 yrs 9 mo | Premedium Pharmaceuticals Private Limited |
Financials of Premedium Pharmaceuticals
Figures of Premedium Pharmaceuticals Private Limited, the primary company behind Premedium Pharmaceuticals, for FY 2025. Revenue was ₹9.67 Cr (+29% year on year). Net profit was ₹1.49 Cr (15% margin). EBITDA was ₹1.55 Cr (16% margin). Revenue has grown at a compounded annual rate of -39% over three years and -29% over five years.
- ₹9.67 CrRevenue · FY 2025 · +29% YoY
- ₹1.49 CrNet profit · 15% margin
- ₹1.55 CrEBITDA · 16% margin
- ₹21.79 CrPaid-up capital
- 12Employees (provident fund records)
- -39%Revenue CAGR, 3 years
- -29%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Premedium Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Premedium Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Premedium Pharmaceuticals
Premedium Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| unither-pharma.com | 1993 | Paris, France | – | – | Contract development and manufacturing organization for proprietary and generic drugs | |
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | – | – | Company offering a suite of R&D and manufacturing services for small molecules and generics | |
| recipharm.com | 1995 | Jordbro, Sweden | – | 1,083 | Pharmaceutical development and manufacturing services are offered contractually. | |
| corerxpharma.com | 2006 | Clearwater, United States | $15M | – | CDMO with a focus on early phase drug product development | |
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. | |
| windlas.com | 2001 | Gurugram, India | $12.96M | 1,264 | Biopharma regulatory affairs, quality control, and strategy services are provided. | |
| medpharm.com | 1998 | Guildford, United Kingdom | – | 108 | Topical and inhaled drug delivery formulations are developed and manufactured. |
Detailed competitors of Premedium Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Premedium Pharmaceuticals
10 companies that operate in the same segment as Premedium Pharmaceuticals (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Premedium Pharmaceuticals
Premedium Pharmaceuticals is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
Premedium Pharmaceuticals has 12 employees.
The primary company behind Premedium Pharmaceuticals, Premedium Pharmaceuticals Private Limited, reported revenue of ₹9.67 Cr for FY 2025, up 29% year on year.
Premedium Pharmaceuticals is an Indian company that produces and supplies innovative pharmaceutical products in sectors like oncology, biosimilars, cardiology, and anti-infectives. They focus on meeting global quality standards through manufacturing with international accreditations and serve healthcare providers worldwide from their base in Gurugram, India, addressing diverse medical needs.
Premedium Pharmaceuticals's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Premedium Pharmaceuticals offers Artepitant 150 IV Injection, Preciplatin 10 Mg, Preciplatin 50 Mg, Artetum Injection 1.5g, and 6 more products and services.
Premedium Pharmaceuticals operates through Premedium Pharmaceuticals Private Limited.
The legal entities of Premedium Pharmaceuticals currently have 5 directors, including Sanjiv Kumar Kothari, Saras Malik, Vivek Anand and others.